Open access
Open access
Powered by Google Translator Translator

Pharmacology/Pharmaceutical Industry

Case-control study: 3 doses of mRNA vaccines were associated with reduced infections with SARS-CoV-2 Omicron and Delta variants compared to no vaccination or 2 doses.

24 Jan, 2022 | 08:56h | UTC

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants – JAMA

Editorial: Booster Vaccination to Prevent COVID-19 in the Era of Omicron: An Effective Part of a Layered Public Health Approach – JAMA

Commentaries: New data show booster doses protect against Omicron – CIDRAP

Boosters provide the best protection against Omicron variant, CDC studies show, raising new questions about what it means to be fully vaccinated – CNN

Related CDC Studies:

COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021 – CDC Morbidity and Mortality Weekly Report

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 – CDC Morbidity and Mortality Weekly Report

 

Commentary on Twitter

 


Updated Guideline: Recommended drugs and biologics in adult patients with COVID-19.

24 Jan, 2022 | 08:52h | UTC

Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19 – Covid-19 Advisory for Ontario

 

Commentary on Twitter (thread – click for more)

 


WHO advisers weigh in on COVID-19 boosters, Pfizer vaccine in younger kids.

24 Jan, 2022 | 08:35h | UTC

WHO advisers weigh in on COVID-19 boosters, Pfizer vaccine in younger kids – CIDRAP

See also: Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing – World Health Organization

 


RCT: In children with peanut allergy, initiation of peanut oral immunotherapy before age 4 years induced desensitization in 71% of patients and remission in 21%.

24 Jan, 2022 | 08:18h | UTC

Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study – The Lancet (link to abstract – $ for full-text)

News Release: Oral immunotherapy induces remission of peanut allergy in some young children – NIH News Releases

Commentary: Peanut Oral Immunotherapy at Younger Age Ups Desensitization in Children – HealthDay

 


Clinical review of subcutaneous Semaglutide for obesity.

24 Jan, 2022 | 07:54h | UTC

Clinical review of subcutaneous semaglutide for obesity – Journal of Clinical Pharmacy and Therapeutics

 


A faster way to find good medical treatments is gaining ground – “A type of clinical trial that tests many therapies at once is being used for COVID and Alzheimer’s”.

24 Jan, 2022 | 07:50h | UTC

A Faster Way to Find Good Medical Treatments Is Gaining Ground – Scientific American

 


Reporting of physicians’ or investigators’ choice of treatment in oncology randomized clinical trials.

24 Jan, 2022 | 07:49h | UTC

Reporting of Physicians’ or Investigators’ Choice of Treatment in Oncology Randomized Clinical Trials – JAMA Network Open

 

Commentary from the author on Twitter (thread – click for more)

 


RCT: Immunogenicity and reactogenicity of different vaccine boosters after a first J&J vaccine.

21 Jan, 2022 | 10:12h | UTC

Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming – New England Journal of Medicine

 

Commentary on Twitter

 


Editorial | Covid-19 vaccines and treatments: we must have raw data, now.

21 Jan, 2022 | 10:00h | UTC

Covid-19 vaccines and treatments: we must have raw data, now – The BMJ

News Release: Editors call for covid-19 vaccine and treatment data to be available for public scrutiny – The BMJ

 


Perioperative guidelines on antiplatelet and anticoagulant agents: 2022 Update.

21 Jan, 2022 | 09:53h | UTC

Perioperative Guidelines on Antiplatelet and Anticoagulant Agents: 2022 Update – Current Anesthesiology Reports

 


Systematic Review: In people with Alzheimer’s disease and vascular dementia with agitation and psychosis, atypical antipsychotics probably reduce agitation slightly (moderate‐certainty evidence) but probably have a negligible effect on psychosis or risk of any adverse event.

21 Jan, 2022 | 09:50h | UTC

Antipsychotics for agitation and psychosis in people with Alzheimer’s disease and vascular dementia – Cochrane Library

Summary: Do antipsychotic medicines reduce  agitated behaviour and psychotic symptoms in people with Alzheimer’s disease and vascular dementia? – Cochrane Library

 


RCT: Lenvatinib plus pembrolizumab improve outcomes compared to chemotherapy in patients with advanced endometrial cancer.

21 Jan, 2022 | 09:46h | UTC

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer – New England Journal of Medicine

 

Commentary on Twitter

 


M-A: No difference in outcomes with Beta-lactam monotherapy vs. combination therapy for bloodstream infections or pneumonia due to P. aeruginosa.

21 Jan, 2022 | 09:37h | UTC

Beta-lactam monotherapy or combination therapy for bloodstream infections or pneumonia due to P. aeruginosa: a meta-analysis – International Journal of Antimicrobial Agents (link to abstract – $ for full-text)

 


M-A: In patients with acute coronary syndrome, a guided approach (i.e., platelet function or genetic testing) to P2Y12 inhibiting therapy may reduce major adverse cardiovascular events without increased risk of bleeding.

21 Jan, 2022 | 09:33h | UTC

Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials – European Heart Journal (link to abstract – $ for full-text)

Commentary: Another Win for Guided P2Y12 Therapy in ACS: Meta-analysis – TCTMD

 

Commentary on Twitter

 


RCT: Lidocaine spray may reduce pain during radial arterial puncture.

21 Jan, 2022 | 09:19h | UTC

Effectiveness of lidocaine spray on radial arterial puncture pain: A randomized double-blind placebo controlled trial – The American Journal of Emergency Medicine (link to abstract – $ for full-text)

 


Booster longevity: Data reveals how long a third shot protects.

20 Jan, 2022 | 09:33h | UTC

Booster longevity: Data reveals how long a third shot protects – NPR

Original Report: SARS-CoV-2 variants of concern and variants under investigation in England – U.K. Health Security Agency

 


A populational-based retrospective cohort study in Qatar showed a reduced risk of Covid-19 breakthrough infections with the Moderna vs. the Pfizer–BioNTech vaccine.

20 Jan, 2022 | 09:30h | UTC

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar – New England Journal of Medicine

 

Commentary on Twitter

 


Short Review: Fluvoxamine for symptomatic outpatients with COVID-19.

20 Jan, 2022 | 09:25h | UTC

Fluvoxamine for symptomatic outpatients with COVID-19 – Canadian Medical Association Journal

Related:

Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know.

Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.

RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19.

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

 


Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.

20 Jan, 2022 | 09:17h | UTC

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis – The Lancet

News Release: An estimated 1.2 million people died in 2019 from antibiotic-resistant bacterial infections, more deaths than HIV/AIDS or malaria – The Lancet

Editorial: Antimicrobial resistance: time to repurpose the Global Fund – The Lancet

Commentary: Antimicrobial resistance now a leading cause of death worldwide, study finds – The Guardian

 

Commentary on Twitter

 


RCT: Among patients with recurrent Clostridioides difficile infection, the use of SER-109, an oral microbiome therapy, reduced recurrence rate compared to placebo (12% vs. 40%).

20 Jan, 2022 | 09:11h | UTC

SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection – New England Journal of Medicine (link to abstract – $ for full-text)

 


Meta-analysis of randomized controlled trials: Drug treatment for panic disorder with or without agoraphobia.

20 Jan, 2022 | 09:06h | UTC

Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials – The BMJ

 


Placebo effect accounts for more than two-thirds of COVID-19 vaccine adverse events, researchers find.

19 Jan, 2022 | 08:53h | UTC

News Release: Placebo effect accounts for more than two-thirds of COVID-19 vaccine adverse events, researchers find – Beth Israel Deaconess Medical Center

Original Study: Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials: A Systematic Review and Meta-analysis – JAMA Network Open

Commentary: ‘Nocebo effect’: two-thirds of Covid jab reactions not caused by vaccine, study suggests – The Guardian

 


RCT: In critically ill adults, using a balanced multielectrolyte solution did not lower the risk of death or acute kidney injury compared to standard saline.

19 Jan, 2022 | 08:41h | UTC

Balanced Multielectrolyte Solution versus Saline in Critically Ill Adults – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Australian study set to guide the treatment of critically ill patients worldwide – George Institute for Global Health

Related:

BaSICS RCT: Among critically ill patients requiring fluid therapy, treatment with a balanced solution did not lead to reduced mortality compared to a 0.9% saline solution.

BaSICS RCT: Among critically ill patients requiring fluid therapy, there was no difference in mortality with slower (333 mL/h) vs. faster (999 mL/h) intravenous fluid bolus rates.

Cochrane Review: Buffered Solutions Do Not Improve Mortality in Critically Ill Adults and Children Compared to 0,9% Saline

 

Commentary on Twitter

 


RCT: In children with community-acquired pneumonia, outpatient antibiotic therapy for 5 days resulted in similar clinical response rates compared to a standard 10-day strategy.

19 Jan, 2022 | 08:39h | UTC

Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children: The SCOUT-CAP Randomized Clinical Trial – JAMA Pediatrics (free for a limited period)

Commentaries:

Trial finds 5 days of antibiotics superior to 10 for kids with pneumonia – CIDRAP

Shorter antibiotics treatment is better for young children with outpatient pneumonia – Vanderbilt University Medical Center

Related:

ACP Guidance: Appropriate Use of Short-Course Antibiotics in Common Infections

RCT: 5 days of high-dose amoxicillin therapy noninferior to 10 days for the treatment of pediatric community-acquired pneumonia

RCT: Among children with community-acquired pneumonia discharged within 48 hours from the ED or hospital, lower-dose outpatient oral amoxicillin was noninferior to a higher dose, and a 3-day duration course was noninferior to 7 days.

Treatment of urinary tract infections in infants <2 Months: A Living Systematic Review – short and long duration of parenteral antibiotics were associated with a similar risk of UTI recurrence.

RCT: 7 days of antibiotic therapy as good as 14 days for afebrile men with urinary tract infection.

Randomized Trial: Seven vs. Fourteen Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia

Meta-Analysis: Efficacy of Short-Course Antibiotic Treatments for Community-Acquired Pneumonia

 


Clinical practice guidelines for therapeutic drug monitoring of teicoplanin.

19 Jan, 2022 | 08:27h | UTC

Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring – Journal of Antimicrobial Chemotherapy

 


Stay Updated in Your Specialty

No spam, just news.